anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: The skeleton embodies an individual's environment and lived experiences. Studying childhood growth disruption can, therefore, aid in understanding the experiences of children in the past. This study evaluates growth disruption in a medieval Toulousian subadult sample to explore factors that may have influenced childhood growth and mortality at this site and to assess the utility of Harris line (HL) interpretations in bioarchaeology.
MATERIALS AND METHODS: Femoral growth disruption was assessed in n = 71 subadults (0.125-12.42 years) from the 10th-13th century St. Étienne cemetery of Toulouse, France, using femoral length, total area, cortical area, and relative cortical area. Femoral radiographs were assessed for HLs. To determine the prevalence of growth disruption, z-scores were calculated using data from the Denver growth study.
RESULTS: The majority of subadults in this sample suffered from femoral growth disruption. Young children (1.0-3.99 years) were the most affected, with >65% experiencing reduced appositional growth and linear growth stunting at time-of-death. Additionally, while many individuals presented with observable HLs, linear and appositional growth did not significantly differ between individuals with and without HLs.
DISCUSSION: Maternal malnutrition and inadequate complementary feeding practices likely contributed to the high prevalence of growth disruption among the youngest individuals in the study. The older children and adolescents buried at St. Étienne experienced an amelioration in growth deficits, indicating an improvement in nutrition and/or disease load. The results of this study suggest that more consideration is required when interpreting the presence/absence of HLs, and that studies assessing HLs may benefit from using a more individualistic approach.
The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
The need for myelographic examination should be carefully evaluated. Iopamidol should be administered with caution in patients with increased intrcranial pressure or suspicion of intracranial tumor, abscess or hematoma, those with a history of convulsive disorder, severe cardiovascular disease, chronic alcoholism, or multiple sclerosis, and elderly patients. Particular attention must be given to state of hydration, concentration of medium, dose, and technique used in these patients. Contrast media may promote sickling in individuals who are homozygous for sickle cell disease when injected intravenously or intra-arterially. Although ISOVUE-M is not injected intravascularly, measurable plasma levels are attained after intrathecal administration of iopamidol. If frankly bloody cerebrospinal fluid is observed, the possible benefits of a myelographic examination should be considered in terms of risk to the patient.   


Patients on anticonvulsant medication should be maintained on this therapy.

Direct intracisternal or ventricular administration for standard radiography (without computerized tomographic enhancement) is not recommended. Inadvertent intracranial entry of a large or concentrated bolus of the contrast medium, which increase the risk of neurotoxicity, can be prevented by careful patient management. Also, effort should be directed to avoid rapid dispersion of the medium causing inadvertent rise to intracranial levels (e.g., by active patient movement). If such intracranial entry of the medium occurs, prophylactic anticonvulsant treatment with diazepam or barbiturates orally for 24 to 48 hours should be considered.

Use of medications that may lower the seizure thresnold (phenothiazine derivatives, including those used for their antihistaminic properties; tricyclic antidepressants; MAO inhibitors; CNS stimulants; analeptics; antipsychotic agents) should be carefully evaluated While the contributory role of such medications has not been established, some physicians have discontinued these agents at least 48 hours before and for at least 24 hours following intrathecal use.

Focal and generalized motor seizures have been reported after intrathecal use of water-soluble contrast agents including iopamidol. In several of those cases reported with iopamidol, higher than recommended doses were employed. Therfore avoid:

  * Deviations from recommended neuroradiologic procedure or patient management.
  * Use in patients with a history of epilepsy unless medically justified.   

  * Overdosage.
  * Intracranial entry of a bolus or premature diffusion of a high concentration of the medium.
  * Failure to maintain elvation of the head during the procedure, on the stretcher, and in bed.
  * Excessive and particularly active patient movement or straining.
This group will not be met face to face and communication will be provided via the website. A username and password will be defined for each user before entering the web page. Visually impaired adolescent girls will be able to individually enter the relevant modules without assistance, read the module they want, and listen to the depicted pictures and graphics. From the admin section of the website, it will be tracked who attended the training, how many minutes they stayed, and how many times a week they attended. The training modules will last 3 weeks and 5 modules will be used in the training. (1st Meeting and Survey collection, 2nd week: 1st and 2nd module, 3rd week: 3 modules and 4th week: 5 modules, 6th interview: after training). A reminder notification will be sent to the contact section on the website every week for them to attend the training.
TAK-137, tablets, orally once on Days 1-7. Dose to be determined from data collected in Cohorts 1-3.
PCT No. PCT/GB95/02991 Sec. 371 Date Jun. 23, 1997 Sec. 102(e) Date Jun. 23, 1997 PCT Filed Dec. 21, 1995 PCT Pub. No. WO96/20011 PCT Pub. Date Jul. 4, 1996A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.
Drug: Ticagrelor 90 mg until 1 year after PPCI (other name: Brillique). Drug: Aspirin 75 mg until 1 year after PPCI.
* Stop ELINESTTM if an arterial thrombotic event or venous thromboembolic (VTE) event occurs.
  * Stop ELINESTTM if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately.
  * If feasible, stop ELINESTTM at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE as well as during and following prolonged immobilization.
  * Start ELINESTTM no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.
  * The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 cases per 10,000 woman-years. The risk of VTE is highest during the first year of use of COCs and when restarting hormonal contraception after a break of 4 weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after use is discontinued.
  * Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes). This risk increases with age, particularly in women over 35 years of age who smoke.
  * Use COCs with caution in women with cardiovascular disease risk factors.
The body image, defined as an individual's 'inner vision' of himself, stems from the combination of multiple factors. The body dissatisfaction, which represents its negative version, is associated with eating disorders, a sedentary lifestyle and weight gain. Several patients suffering from obesity consider weight loss as a strategy to work on their body image. Multiples studies confirm a positive association between weight loss and improved body images. Nevertheless, few elements seem to predispose to body dissatisfaction persistence, such as a history of strict diets, eating disorders or other psychopathologies. To treat body dissatisfaction, we need to focus our attention on self-esteem, a balanced lifestyle, and media education.
Physical activity (PA) is one of the major determinants of health. Indeed, the practice of a physical activity, even moderate, plays an important role in the prevention and the management of the main chronic non-communicable diseases (cardiovascular diseases, certain cancers, diabetes, obesity, osteoporosis ...) as well as by improving psychological health. The effects are beneficial regardless of age, gender and state of health. Moreover, in addition to the well-being of employees, several studies have shown that physical activity has a positive impact on the economy of companies via the reduction of absenteeism and the improvement of productivity. Today, the World Health Organization (WHO) prescribes 150 min of physical activity per week regardless of the person's profile (active employee, employee working in his office, construction worker, etc.).. In this project,the investigators therefore want to test the physical qualities of employees in order to prescribe the best possible dose of physical activity with the ultimate goal of improving quality of life.
PROBLEM TO BE SOLVED: To obtain a peptide-containing food having a hypotensor action by formulating an oligopeptide obtained by hydrolyzing a dried bonito with an enzyme. SOLUTION: This peptide-containing food contains an oligopeptide obtained by hydrolyzing a dried bonito with an enzyme. Preferably, thermolysin derived from a microorganism is used as the enzyme. When thermolysin is used, a product containing 0.1-0.3 wt.% of Leu-Lys-Pro-Asn-Met (Leu is leucine; Lys is Lysine; Pro is proline; Asn is asparagine; Met is methionine) as an oligopeptide having an excellent angiotensin transferase inhibiting effect is obtained. Preferably, hydrolysis is performed by using an enzyme in an amount of 0.1-1 wt.% based on the total of the dried bonito and water so as to a final hydrolysis fraction be 5-30% at 30-60 deg.C and pH 4-8 for 3-20 hrs. Preferably, the most exceeding effect is exhibited when tea is used as the food. Preferably, an oligopeptide may be formulated with the tea at a weight ratio of (oligopeptide/tea) is (70/30)-(55/45).
Olfactory neuroblastoma (ONB) is an uncommon malignant tumor typically located in the upper nasal cavity. Olfactory neuroblastoma originating in the nasopharynx is extremely rare and tends to be misdiagnosed. The authors describe a rare case of ONB arising ectopically in the nasopharynx. The patient was a 65-year-old woman with recurrent epistaxis and a feeling of fullness in the right ear. After evaluation, endoscopic surgery was performed. The pathological result proved to be ONB. Postoperative magnetic resonance imaging showed that the tumor was completely resected. The patient proceeded to have 66 Gy of postoperative intensity-modulated radiotherapy and was followed for 36 months without tumor recurrence. Olfactory neuroblastoma originating from the nasopharynx is more rare condition compared with ONB located in other areas in the literature. The symptoms of ONB ectopic to the nasopharynx are similar to those of other nasopharyngeal tumors, which were likely to be misdiagnosed. The treatment principle is the same as that of nonectopic ONB, which is surgery combined with radiotherapy. Surgery can be performed using an endoscopic transnasal approach.
The Ministry of Health Malaysia aims to fully replace liquid-based cytology (LBC) with Human Papillomavirus (HPV) tests and increase the screening coverage from a baseline of 25% to 40% by 2023, followed by a 10% yearly increment until 70% coverage. This transition requires proper planning, including the number of tests needed and budget allocation. This study aims to simulate different transition strategies involving the shift from LBC to HPV testing with expanded screening coverage to predict their impact on cervical cancer elimination in Malaysia. A system dynamics model was developed to simulate the transition from LBC to HPV testing and HPV vaccination coverage in Malaysia. The dynamic model utilised local epidemiological data, published research, and expert opinion when data was unavailable. The simulation showed that a combination of high HPV vaccination coverage and transitioning fully to five-yearly HPV testing by 2030, coupled with a 70% screening uptake by 2040, would accelerate cancer elimination in Malaysia by 18 years with an estimated screening cost of MYR1.81 billion equivalent to USD 411 millions compared to the baseline of using LBC as the primary screening method (MYR1.39 billion, USD 315 millions). Sustained, it would lead to averting 6,000 new cancer cases by 2070. Alternatively, conducting HPV screenings twice before age 50 would advance cervical cancer elimination by 14 years and prevent approximately 1000 new cases by 2070, with an estimated cost of MYR1.13 billion equivalent to USD 257 millions. A delay in achieving the full transition prolonged the elimination more than a delay in increasing the screening coverage. In all scenarios, yearly vaccination of 90% of girls age 13 is crucial to achieving elimination. In the Malaysian context, where HPV vaccination coverage has reached considerable levels, the evidence advocates for a full transition from LBC to HPV testing, ideally by 2030. While expanding screening coverage remains a critical factor in this endeavour, the findings unequivocally endorse prioritising the transition process. Trial registration: Trial registration number: NMRR ID-22-00187-DJU.
The invention relates to an antitubercular pure Chinese medicine for treating tuberculosis, which is prepared from pure Chinese medicines. The antitubercular pure Chinese medicine is prepared from sixteen pure Chinese medicinal components such as prunella vulgaris, clivers, yellowtop, ash bark and radix stemonae. The Chinese medicines are ground, extracted according to a water extract method, an ethanol extract method and the like respectively and condensed into thick paste, and the thick paste is subjected to spray drying so as to turn into powder. Clinical observation shows that the medicine has obvious efficacy of inhibiting the development and formation of incipient pulmonary tuberculosis, pulmonary tuberculosis in infective period, infiltrative type pulmonary tuberculosis, cavernous pulmonary tuberculosis, lymphatic tuberculosis, soft tissue tuberculosis and even bone tuberculosis, has the characteristics of no drug tolerance, no toxic property and no harm from long-term taking as compared with the prior Western antitubercular medicine, and is an ideal pure Chinese antiphthisic medicine (antitubercular medicine) at present. A large number of clinical trials prove that the medicine has the special effects, and pharmacodynamic analysis further proves the efficacy of the medicine at the same time. Toxicological tests for the medicine prove that the medicine has no toxic side effects. A large number of clinical trials prove that the medicine has the antiphthisic cure rate up to more than 85 percent and has the total effective rate up to more than 95 percent.
Chronic traumatic encephalopathy (CTE) is defined by perivascular neuronal phosphorylated-tau accumulation at cortical sulcal depths. CTE has been mainly described in the context of repetitive, impact-type traumatic brain injury (rTBI), principally from contact sports. Rarely, CTE has been associated with single TBIs, including in relationship to healed leucotomy sites in brains from formerly institutionalized psychiatric patients without documented rTBI. Given that leucotomy principally involves severing of white matter, this could suggest involvement of axonal injury in CTE pathophysiology. We present three cases wherein isolated CTE pathology was identified adjacent to distinct white matter lesions. Case 1 is a 41-year-old man with history of hereditary hemorrhagic telangiectasia and resection of a cerebral arteriovenous malformation (AVM). Case 2 is a 46-year-old man with glioblastoma. Case 3 is a 52-year-old man with a remote cerebral infarct. Isolated CTE lesions were found adjacent to the aforementioned pathologies in each case. Additional CTE lesions were not identified despite extensive sampling. Multiple age-related tau astrogliopathy (ARTAG)-like lesions were also identified at other sulcal depths near the AVM resection site in Case 1. These cases may provide insights regarding the pathophysiology of the CTE pathognomonic lesion and the development of ARTAG-like pathology adjacent to long-standing mass lesions.
A method is described for operating a distributed processing, interactive computer network. The network is intended to provide very large numbers of simultaneous users access to large numbers of applications which include pre-created, interactive text/graphic sessions. The network includes one or more servers, interactive applications, and one or more user reception systems. The respective reception systems are designed to and are capable of communicating with the respective servers and receiving applications from them. The respective reception systems feature a display interface, as well as reception system software, operating system software and CPU for executing the applications and presenting applications to respective users. The method features steps for preparing the applications in a high-level programing language so that the applications may be executed at the respective reception systems independently of the reception system CPU type and operating system type by interpreting the respective applications at runtime with an interpreter available at the respective reception systems. In accordance with the method, the applications are divided into sections and structured with objects of multiple types containing application display data and/or program code. The objects are distributed in the network and provided at run time at a reception system at which the respective applications are requested. The method further features steps for providing the respective application programs with a structure that features a header section, data structure section and code section implemented in objects. In this arrangement, method steps are provides to enable respective application programs code section to include one or more procedures for supporting system services, the procedures including a key word for identifying the respective procedures. Additionally, the method includes steps for enabling application program data structure section to identifying the data structure for the respective application programs. Further, the method includes steps for enabling the respective application program structure to include a header section that identifies the respective application program names.
The invention discloses an insole containing traditional Chinese medicine. The insole containing traditional Chinese medicine comprises an insole body. A hollow containing space is formed in the insole body, a filling layer is laid in the hollow containing space, and the filling layer comprises the powder components of 5 g of azedarach, 8 g of roots of apocynum venetum, 6 g of raspberries, 1 g of crocus sativus, 1 g of rosa laevigata, 0.01 g of fructus cnidii and 0.5 g of duck wheat. Compared with the prior art, the insole containing traditional Chinese medicine has the better effect of eliminating and restraining bacteria of dermatophytosis and foot odor, the dermatophytosis and foot odor can be thoroughly cured and after a patient with the severe dermatophytosis and foot odor uses the insole for two months, and the patient does not relapse any more. In addition, the patient only needs to place the insole in a shoe worn every day without operation like smearing unguent repeatedly, use is convenient, the effect of treating the dermatophytosis and foot odor from the external portion is achieved, the Yongquan acupoint is stimulated through acupuncture points at the sole, then the conception vessel and governor vessel are adjusted, and the purpose of adjusting the viscera is achieved. After the patient uses the insole for a long time, the symptoms that the feet are cold and the soles perspire during sleep can be relieved effectively, the spleen and stomach can be adjusted, and no toxic and side effect exists.
Patients undergoing maintenance hemodialysis (MHD) are a high-risk group susceptible to SARS-CoV-2 infection and long-COVID syndrome appearance. However, there is limited and unclear evidence for long COVID in MHD patients. We collected the general information, symptoms, signs and laboratory indices of 366 MHD patients infected with COVID-19 and conducted 12 months follow-up with a series of questionnaires. As a result, 285 MHD patients had long COVID, with the most common symptoms were fatigue (84.69%) and muscle weakness (72.45%). Mobility problem (p < 0.001), anxiety/depression (p = 0.002) and breathlessness (p < 0.001) were more prevalent in long COVID patients than in non-long COVID patients. Persistent long COVID people were more likely to report all domains problems of the EQ-5D-5L. Age, female, inadequate dialysis (Kt/V < 1.2), coagulation abnormalities (d-dimer > 1 mg/L) and more comorbidities were risk factors for the development of long COVID. In addition to these factors, elevated inflammatory markers (CRP > 10 mg/L) represent an extra risk factor for the persistence of long COVID symptoms in MHD patients. And more than 80% of long COVID symptoms would resolve after 1 year in MHD patients, of which the sixth month after COVID-19 infection is a critical turning point. In conclusion, more than 68% of MHD patients have long COVID, which has a poor impact on their health status and quality of life. These risk factors for the development and persistence of long COVID deserve the attention of clinicians.
FIELD: medicine, pharmacology. SUBSTANCE: method of prognosis of hypotensive therapy efficiency with calcium antagonists is carried out by study of pharmacokinetics of preparation to be tested. Pyridinol carbamate is used as a test-preparation that is given as a single dose. Pharmacokinetics is investigated in saliva. Sensitivity to calcium antagonists, for example nifedipin, that is metabolized by oxidation is assayed also. EFFECT: enhanced sensitivity of method.